Disease Activity

Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study
Philip J Mease, Dafna D Gladman, Atul Deodhar, Dennis G McGonagle, Peter Nash, Wolf-Henning Boehncke, Alice Gottlieb, Xie L Xu, Stephen Xu, Elizabeth C Hsia, Chetan S Karyekar, Philip S Helliwell

RMD Open Jul 2020, 6 (2) e001217; DOI: 10.1136/rmdopen-2020-001217
Rheumatology practice amidst the COVID-19 pandemic: a pragmatic view
Vasco C Romão, Inês Cordeiro, Carla Macieira, Filipa Oliveira-Ramos, José Carlos Romeu, Carlos Miranda Rosa, Maria João Saavedra, Fernando Saraiva, Elsa Vieira-Sousa, João Eurico Fonseca

RMD Open Jun 2020, 6 (2) e001314; DOI: 10.1136/rmdopen-2020-001314
Body mass index and treatment survival in patients with RA starting treatment with TNFα-inhibitors: long-term follow-up in the real-life METEOR registry
Sytske Anne Bergstra, Cornelia F Allaart, David Vega-Morales, Marieke De Buck, Elizabeth Murphy, Karen Salomon Escoto, Tom W J Huizinga

RMD Open Jun 2020, 6 (2) e001203; DOI: 10.1136/rmdopen-2020-001203
Earlier is better when treating rheumatoid arthritis: but can we detect a window of opportunity?
Sytske Anne Bergstra, Joy A Van Der Pol, Naghmeh Riyazi, Yvonne P M Goekoop-Ruiterman, Pit J S M Kerstens, Willem Lems, Tom W J Huizinga, Cornelia F Allaart

RMD Open May 2020, 6 (1) e001242; DOI: 10.1136/rmdopen-2020-001242
Association of body mass index on disease activity in axial spondyloarthritis: systematic review and meta-analysis
Jean W Liew, Irvin J Huang, Diana N Louden, Namrata Singh, Lianne S Gensler

RMD Open May 2020, 6 (1) e001225; DOI: 10.1136/rmdopen-2020-001225
Assessment of the Patient Acceptable Symptom State (PASS) in psoriatic arthritis: association with disease activity and quality of life indices
Ennio Lubrano, Silvia Scriffignano, Ana Belen Azuaga, Julio Ramirez, Juan D Cañete, Fabio Massimo Perrotta

RMD Open Mar 2020, 6 (1) e001170; DOI: 10.1136/rmdopen-2020-001170
Eligibility criteria for biologic disease-modifying antirheumatic drugs in axial spondyloarthritis: going beyond BASDAI
Jose Marona, Alexandre Sepriano, Santiago Rodrigues-Manica, Fernando Pimentel-Santos, Ana Filipa Mourão, Nélia Gouveia, Jaime Cunha Branco, Helena Santos, Elsa Vieira-Sousa, Filipe Vinagre, João Tavares-Costa, João Rovisco, Miguel Bernardes, Nathalie Madeira, Rita Cruz-Machado, Raquel Roque, Joana Leite Silva, Mary Lucy Marques, Raquel Miriam Ferreira, Sofia Ramiro

RMD Open Jan 2020, 6 (1) e001145; DOI: 10.1136/rmdopen-2019-001145
Prognosis of pneumonia in patients with rheumatoid arthritis: the role of medication and disease activity prior to admission a population-based cohort study
Mette Holland-Fischer, Reimar W Thomsen, Ulrik Tarp, Mette Nørgaard

RMD Open Feb 2020, 6 (1) e001102; DOI: 10.1136/rmdopen-2019-001102
Timing matters: real-world effectiveness of early combination of biologic and conventional synthetic disease-modifying antirheumatic drugs for treating newly diagnosed polyarticular course juvenile idiopathic arthritis
Bin Huang, Tingting Qiu, Chen Chen, Yin Zhang, Michael Seid, Dan Lovell, Hermine I Brunner, Esi M Morgan

RMD Open Jan 2020, 6 (1) e001091; DOI: 10.1136/rmdopen-2019-001091
Early non-response to certolizumab pegol in rheumatoid arthritis predicts failure to achieve low disease activity at 1 year: data from a prospective observational study
Alain Saraux, René-Marc Flipo, Francis Fagnani, Jacques Massol, Gabrielle Cukierman, Jean-Michel Joubert, Philippe Huot-Marchand, Bernard Combe

RMD Open Jan 2020, 6 (1) e000991; DOI: 10.1136/rmdopen-2019-000991

Main menu

Disease Activity

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Disease Activity

Pages